Equillium_Square_Logo.png
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
March 30, 2021 16:01 ET | Equillium
Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Dose-dependent changes in pharmacodynamic markers observed with subcutaneous dosing...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
March 29, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 25, 2021 16:15 ET | Exagen Inc.
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. Announces Pricing of Public Offering of Common Stock
March 22, 2021 22:01 ET | Exagen Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. Announces Proposed Public Offering of Common Stock
March 22, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
March 16, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
March 15, 2021 11:12 ET | BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
Equillium_Square_Logo.png
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 15, 2021 08:00 ET | Equillium
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...
Ronald L. Besser announces the publication of ‘The Origins of AIDS and Autism’
March 03, 2021 00:00 ET | Archway Publishing
YORK, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Recent release “The Origins of AIDS and Autism” (published by Archway Publishing) is a collaboration between the Life Laboratory of Spirit and author...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
March 02, 2021 08:00 ET | Exagen Inc.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the...